|Western Blot (WB)||0.5-2 µg/ml|
|Tested Species reactivity||Human, Mouse, Non-human primate, Rat|
|Host / Isotype||Mouse / IgG2b, Kappa|
|Immunogen||A C-terminal portion of the human p90 protein.|
|Storage buffer||sodium borate|
|Storage conditions||4° C, store in dark|
Inhibition of protein phosphatase 2A (PP2A) activity has been identified as a prerequisite for the transformation of human cells. The protein, designated Cancerous Inhibitor of PP2A (CIP2A), interacts directly with the oncogenic transcription factor c-Myc, inhibits PP2A activity toward c-Myc serine 62 (S62), and thereby prevents c-Myc proteolytic degradation. In addition to its function in c-Myc stabilization, CIP2A promotes anchorage-independent cell growth and in vivo tumor formation. The oncogenic activity of CIP2A is demonstrated by transformation of human cells by overexpression of CIP2A. Importantly, CIP2A is overexpressed in two common human malignancies, head and neck squamous cell carcinoma (HNSCC) and colon cancer.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Protein Aliases: Cancerous inhibitor of PP2A; cancerous inhibitor of protein phosphatase 2A; CIP2A; p90 autoantigen; p90 autoantigen homolog; Protein CIP2A
Gene Aliases: AA408511; AU018569; CIP2A; KIAA1524; p90
If an Invitrogen™ antibody doesn’t perform as described on our website or datasheet, we’ll replace the product at no cost to you, or provide you with a credit for a future purchase.*
Get expert recommendations for common problems or connect directly with an on staff expert for technical assistance related to applications, equipment and general product use.